Transcranial Magnetic Stimulation in the Treatment of Negative Symptoms of Schizophrenia (original) (raw)

2021, JOMENAS Press

The negative symptoms of schizophrenia are core components of schizophrenia that remain a clinical conundrum. It accounts for a large part of long-term disability and poor functional outcomes in patients with the disorder. The treatment options for the negative symptoms and cognitive deficits seen in schizophrenia continue to be limited despite recent psychopharmacology advancements. A functional abnormality in the prefrontal cortex (PFC) has been implicated in the pathogenesis of negative symptoms of schizophrenia, and non-invasive neurostimulation using repetitive transcranial magnetic stimulation has been mooted as an add-on treatment option in the amelioration of negative symptoms in schizophrenia. This study aims to review the published studies regarding Repetitive Transcranial Magnetic Stimulation (rTMS) to alleviate the negative symptoms of schizophrenia. 52 relevant articles were found from PubMed and Google Scholar using the following Mesh terms' Schizophrenia', 'Negative symptoms of schizophrenia, 'Transcranial magnetic stimulation, and 'Treatment' and 35 relevant articles were selected after a thorough screening process. The available evidence indicates that transcranial magnetic stimulation has found a root in the treatment of conditions such as depression, migraine, Obsessive-Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), and anxiety. There have been indicators from trials that Transcranial Magnetic Stimulation (TMS) could have a role in improving negative symptoms of schizophrenia, particularly when used as an adjunct to established pharmacological treatment. However, the current findings have been inconsistent with a relatively small sample size; hence larger multicenter studies may be required to prove the treatment significance before it becomes a mainstream and acceptable treatment option.

A review of transcranial magnetic stimulation for treating negative symptoms of schizophrenia

European Psychiatry, 2016

IntroductionThe finding of prefrontal dysfunction in schizophrenia patients with negative symptoms (NS) has raised interest in using transcranial magnetic stimulation (TMS), which can modulate prefrontal function and dopamine release, as potential treatment for NS.ObjectiveTo briefly review current literature concerning the use of TMS as treatment for NS.AimsTo assess whether current evidence supports the use of TMS for NS.MethodsNarrative review of articles found through a PubMed database search using the keywords “transcranial magnetic stimulation”, “schizophrenia”, and “negative symptoms” between 1998 and 2015.ResultsUp to date, reviews of randomized sham-controlled studies found positive effects of TMS in NS. However, they exposed several methodological difficulties. More recent studies, reviewed in this poster, tried to overcome these, using results from multiple centers, larger samples and blinding. Various TMS techniques were studied, differing in frequency, motor threshold (...

Efficacy of bilateral repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: results of a multicenter double-blind randomized controlled trial

Psychological medicine, 2015

Few studies have investigated the efficacy of repetitive transcranial magnetic stimulation (rTMS) treatment for negative symptoms of schizophrenia, reporting inconsistent results. We aimed to investigate whether 10 Hz stimulation of the bilateral dorsolateral prefrontal cortex during 3 weeks enhances treatment effects. A multicenter double-blind randomized controlled trial was performed in 32 patients with schizophrenia or schizo-affective disorder, and moderate to severe negative symptoms [Positive and Negative Syndrome Scale (PANSS) negative subscale ⩾15]. Patients were randomized to a 3-week course of active or sham rTMS. Primary outcome was severity of negative symptoms as measured with the Scale for the Assessment of Negative Symptoms (SANS) and the PANSS negative symptom score. Secondary outcome measures included cognition, insight, quality of life and mood. Subjects were followed up at 4 weeks and at 3 months. For analysis of the data a mixed-effects linear model was used. A ...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.